East West Med Res Inst

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes8 trials
• Obesity7 trials
• Type 1 diabetes1 trial

Phase

• Phase 313 trials

Status

• Completed8 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Novo Nordisk A/S13 trials

Running trials

• Recruiting

  Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

  NCT07817251· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

  NCT07770841· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

  NCT07745504· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· Phase 3· Novo Nordisk A/S· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity2 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

  NCT06131437· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)

  NCT05823948· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

  NCT05013229· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source